A 6-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Irritability Associated With Autistic Disorder
Latest Information Update: 30 Jan 2024
Price :
$35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 15 Sep 2020 Results (n=537) of post-hoc pooled analysis assessing safety and efficacy of Lurasidone from six double blind, placebo-controlled, 6 weeks clinical studies in adolescents and young adults with schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 18 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.